Epilepsy Surgery Outcome in Children With Tuberous Sclerosis Complex Evaluated With α-[11C]Methyl-L-Tryptophan Positron Emission Tomography (PET)

Abstract

Tuberous sclerosis complex is commonly associated with medically intractable seizures. We previously demonstrated that high uptake of α-[¹¹C]methyl-L-tryptophan (AMT) on positron emission tomography (PET) occurs in a subset of epileptogenic tubers consistent with the location of seizure focus. In the present study, we analyzed the surgical outcome of children with tuberous sclerosis complex in relation to AMT PET results. Seventeen children (mean age 4.7 years) underwent epilepsy surgery, guided by long-term videoelectroencephalography (EEG) (including intracranial EEG in 14 cases), magnetic resonance imaging (MRI), and AMT PET. AMT uptake values of cortical tubers were measured using regions of interest delineated on coregistered MRI and were divided by the value for normal-appearing cortex to obtain an AMT uptake ratio. Based on surgical outcome data, tubers showing increased AMT uptake (uptake ratio greater than 1.00) were classified into three categories: (1) epileptogenic (tubers within an EEG-defined epileptic focus whose resection resulted in seizure-free outcome), (2) nonepileptogenic (tubers that were not resected but the patient became seizure free), or (3) uncertain (all other tubers). Increased AMT uptake was found in 30 tubers of 16 children, and 23 of these tubers (77%) were located in an EEG-defined epileptic focus. The tuber with the highest uptake was located in an ictal EEG onset region in each patient. Increased AMT uptake indicated an epileptic region not suspected by scalp EEG in four cases. Twelve children (71%) achieved seizure-free outcome (median follow-up 15 months). Based on outcome criteria, 19 of 30 tubers (63%) with increased AMT uptake were epileptogenic, and these tubers had significantly higher AMT uptake than the nonepileptogenic ones (P = .009). Tubers with at least 10% increase of AMT uptake (in nine patients) were all epileptogenic. Using a cutoff threshold of 1.02 for AMT uptake ratio provided an optimal accuracy of 83% for detecting tubers that needed to be resected to achieve a seizure-free outcome. The findings suggest that resection of tubers with increased AMT uptake is highly desirable to achieve seizure-free surgical outcome in children with tuberous sclerosis complex and intractable epilepsy. AMT PET can provide independent complementary information regarding the localization of epileptogenic regions in tuberous sclerosis complex and enhance the confidence of patient selection for successful epilepsy surgery. (J Child Neurol 2005;20:429—438).

Get full access to this article

View all access options for this article.

References

Roach ES , DiMario FJ , Kandt RS , Northrup H. : Tuberous Sclerosis Consensus Conference: Recommendations for diagnostic evaluation. National Tuberous Sclerosis Association. J Child Neurol 1999;14:401—407.

Fryer AE , Chalmers A. , Connor JM , et al: Evidence that the gene for tuberous sclerosis is on chromosome 9. Lancet 1987;i:659—661.

Kandt RS , Haines JL , Smith M. , et al: Linkage of an important gene locus for tuberous sclerosis to a chromosome 16 marker for polycystic kidney disease. Nat Genet 1992;2:37—41.

Gomez MR Neurologic and psychiatric features, in Gomez MR (ed): Tuberous Sclerosis, 2nd ed. New York, Raven Press, 1988, 21—36.

Webb DW , Fryer AE , Osborne JP : Morbidity associated with tuberous sclerosis: A population study. Dev Med Child Neurol 1996; 38:146—155.

Baumgartner JE , Wheless JW , Kulkarni S. , et al: On the surgical treatment of refractory epilepsy in tuberous sclerosis complex. Pediatr Neurosurg 1997;27:311—318.

Sinson G. , Sutton LN , Yachnis AT , et al: Subependymal giant cell astrocytomas in children. Pediatr Neurosurg 1994;20:233—239.

Di Rocco C , Iannelli A. , Marchese E. : On the treatment of subependymal giant cell astrocytomas and associated hydrocephalus in tuberous sclerosis. Pediatr Neurosurg 1995;23:115—121.

Cuccia V. , Zuccaro G. , Sosa F. , et al: Subependymal giant cell astrocytoma in children with tuberous sclerosis. Childs Nerv Syst 2003;19:232—243.

10.

Bebin EM , Kelly PJ , Gomez MR : Surgical treatment for epilepsy in cerebral tuberous sclerosis. Epilepsia 1993;34:651—657.

11.

Avellino AM , Berger MS , Rostomily RC , et al: Surgical management and seizure outcome in patients with tuberous sclerosis. J Neurosurg 1997;87:391—396.

12.

Guerreiro MM , Andermann F. , Andermann E. , et al: Surgical treatment of epilepsy in tuberous sclerosis. Strategies and results in 18 patients. Neurology 1998;51:1263—1269.

13.

Koh S. , Jayakar P. , Dunoyer C. , et al: Epilepsy surgery in children with tuberous sclerosis complex: Presurgical evaluation and outcome. Epilepsia 2000;41:1206—1213.

14.

Jarrar RG , Buchalter JR , Raffel C. : Long-term outcome of epilepsy surgeryinpatientswithtuberoussclerosis. Neurology 2004;62:479—481.

15.

Roach ES , Williams DP , Laster DW : Magnetic resonance imaging in tuberous sclerosis. Arch Neurol 1987;44:301—303.

16.

Nixon JR , Houser OW , Gomez MR , Okazaki H. : Cerebral tuberous sclerosis: MR imaging. Radiology 1989;170:869—873.

17.

Cusmai R. , Chiron C. , Curatolo P. , et al: Topographic comparative study of magnetic resonance imaging and electroencephalographyin 34patientswith tuberoussclerosis. Epilepsia 1990;31:747—755.

18.

Takanashi J. , Sugita K. , Fujii K. , Niimi H. : MR evaluation of tuberous sclerosis: Increased sensitivity with fluid-attenuated inversion recovery and relation to severity of seizures and mental retardation. AJNR Am J Neuroradiol 1995;16:1923—1928.

19.

Jansen FE , Braun KP , van Nieuwenhuizen O. , et al: Diffusion-weighted magnetic resonance imaging and identification of the epileptogenic tuber in patients with tuberous sclerosis. Arch Neurol 2003;60:1580—1584.

20.

Szelies B. , Herholz K. , Heiss WD , et al: Hypometabolic cortical lesions in tuberous sclerosis with epilepsy: Demonstration by positron emission tomography. J Comput Assist Tomogr 1983;7:946—953.

21.

Rintahaka PJ , Chugani HT : Clinical role of positron emission tomography in children with tuberous sclerosis complex. J Child Neurol 1997;12:42—52.

22.

Chugani DC , Chugani HT , Muzik O. , et al: Imaging epileptogenic tubers in children with tuberous sclerosis complex using α-[11C] methyl-L-tryptophan positron emission tomography . Ann Neurol 1998;44:858—866.

23.

Asano E. , Chugani DC , Muzik O. , et al: Multimodality imaging for improved detection of epileptogenic foci in tuberous sclerosis complex. Neurology 2000;54:1976—1984.

24.

Asano E. , Chugani DC , Juhász C. , et al: Surgical treatment of West syndrome. Brain Dev 2001;23:668—676.

25.

Engel J. Jr, Van Ness PC , Rasmussen TB , Ojemann LM : Outcome with respect to epileptic seizures, in Engel J Jr (ed): Surgical Treatment of the Epilepsies, 2nd ed. New York, Raven Press, 1993, 609—621.

26.

Spencer SS , Guimaraes P. , Katz A. , et al: Morphological patterns of seizures recorded intracranially. Epilepsia 1992;33:537—545.

27.

Bergstrom M. , Litton J. , Eriksson L. , et al: Determination of object contour from projections for attenuation correction in cranial positron emission tomography . J Comput Assist Tomogr 1982;6:365—372.

28.

Woodard HQ , Bigler RE , Freed B. : Expression of tissue isotope distribution, letter. J Nucl Med 1975;16:958—959.

29.

Chugani DC , Muzik O. , Chakraborty P. , et al: Human brain serotonin synthesis capacity measured in vivo with alpha-[11C]-methyl-L-tryptophan. Synapse 1998 ;28:33—43.

30.

Pietrzyk U. , Herholz K. , Fink G. , et al: An interactive technique for three-dimensional image registration: Validation for PET, SPECT, MRI and CT brain studies. J Nucl Med 1994;35:2011—2018.

31.

Kennedy DN , Filipek PA , Caviness VS Jr: Anatomic segmentation and volumetric calculations in nuclear magnetic resonance imaging. Trans Med Imaging 1989;8:1—7.

32.

Aston JA , Cunningham VJ , Asselin MC , et al: Positron emission tomography partial volume correction: Estimation and algorithms. J Cereb Blood Flow Metab 2002 ;22:1019—1034.

33.

Mazziotta JC , Phelps ME , Plummer D. , Kuhl DE : Quantitation in positron emission computed tomography: 5. Physical-anatomical effects. J Comput Assist Tomogr 1981;5:734—743.

34.

Javoy-Agid F. , Scatton B. , Ruberg M. , et al: Distribution of monoaminergic, cholinergic, and GABAergic markers in the human cerebral cortex. Neuroscience 1989;29:251—259.

35.

Tamaki K. , Okuno T. , Iwasaki Y. , et al: Regional cerebral blood flow in relation to MRI and EEG findings in tuberous sclerosis. Brain Dev 1991;13:420—424.

36.

Koh S. , Jayakar P. , Resnick T. , et al: The localization value of ictal SPECT in children with tuberous sclerosis complex and refractory partial epilepsy. Epileptic Disord 1999;1:41—46.

37.

Asano E. , Chugani DC , Juhász C. , et al: Epileptogenic zones in tuberous sclerosis complex: Subdural EEG versus MRI and FDG PET, abstract. Epilepsia 2000;41(Suppl 7):128.

38.

Becker AJ , Urbach H. , Scheffler B. , et al: Focal cortical dysplasia of Taylor's balloon cell type: Mutational analysis of the TSC1 gene indicates a pathogenic relationship to tuberous sclerosis. Ann Neurol 2002;52:29—37.

39.

Chugani HT , Shields WD , Shewmon DA , et al: Infantile spasms: I. PET identifies focal cortical dysgenesis in cryptogenic cases for surgical treatment. Ann Neurol 1990;27:406—413.

40.

Chugani HT , Shewmon DA , Shields WD , et al: Surgery for intractable infantile spasms: Neuroimaging perspectives . Epilepsia 1993;34:764—771.

41.

Desbiens R. , Berkovic SF , Dubeau F. , et al: Life-threatening focal status epilepticus due to occult cortical dysplasia. Arch Neurol 1993;50:695—700.

42.

Theodore WH , Newmark ME , Sato S. , et al: [18F]Fluorodeoxyglucose positron emission tomography in refractory complex partial seizures. Ann Neurol 1983; 14: 429—437.

43.

Sadzot B. , Debets RM , Maquet P. , et al: Regional brain glucose metabolism in patients with complex partial seizures investigated by intracranial EEG. Epilepsy Res 1992;12:121—129.

44.

Henry TR , Mazziotta JC , Engel J. Jr: Interictal metabolic anatomy of mesial temporal lobe epilepsy. Arch Neurol 1993;50:582—589.

45.

Juhász C. , Chugani DC , Muzik O. , et al: Relationship of flumazenil and glucose PET abnormalities to neocortical epilepsy surgery outcome. Neurology 2001;56:1650—1658.